DBCG – SKAGEN TRIAL 1

ddmmyy

DANISH BREAST CANCER COOPERATIVE GROUP Loco-regional RT 50 Gy versus 40			sus 40 Gy
Name – patient ID	Hospital, department		
Day Month year No.			
Instructions: This form should be completed before inclusion in the protocol. Only if all the boxes of the			
selected column is ticked, the patient is suitable for treatment according to the protocol.			
The form is available on DBCG's website (<u>www.dbcg.dk</u>). Choose the Web entry menu, enter Username and Password, follow the instructions as described.			
Inclusion criteria:			
Histologically proven invasive breast carcinoma pT1-3, pN0-N3, M0 or operated after ges g no			
primary systemic therapy for inv. breast carcinoma ypT0-3, ypN0-3, M0			
Candidate for regional nodes RT without nodal boost			□ no
Woman aged ≥ 18 years		□ yes	□ no
WHO performance 0-2		□ yes	□ no
Randomisation within 42 days after last surgery or			🗆 no
within 4 weeks after last chemotherapy			
Capable of completing therapy, planned follow up visits and investigations			□ no
Fertile women: uses contraception if relevant			□ no
Charlsons morbidity form and pathology form are available			□ no
Informed approval to trial (signed patient folder):		□ yes	□ no
dd mm yy			
Exclusion criteria:			
Bilateral breast carcinoma			□ yes
			-
Previous RT to breast / thorax			□ yes
Concurrent / previous malignancy which may influence therapy or follow up			□ yes
Pregnant or lactating			□ yes
Surgery	Mastectomy		
	Lumpectomy		
Systemic therapy	Endocrine or no systemic thera		
Boost	Chemotherapy (incl. endocrine no	/ trastuz	umab)
Boost			
Connective tissue disease	🗆 no 🛛 yes		
If yes; diagnosis			
Filled by DBCG	Form filled in by:		
Randomization no.			
Result of randomization :	Name:		
Regime 1 (Radiotherapy 40 Gy / 15 fr)	(CAPITAL LETTERS)		
Regime 2 (Radiotherapy 50 Gy / 25 fr)	Sign.:		

ddmmyy

Date

Date

INCLUSION FORM